Horizon to acquire GE’s gene tech business Dharmacon
Dharmacon, which manufactures RNAi products, has a portfolio of gene editing products, particularly in CRISPR reagents and arrayed libraries. It had generated revenues of $36.7m in 2016 with an EBITDA of $5.4m.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.